Your browser is no longer supported. Please, upgrade your browser.
Acorda Therapeutics, Inc.
Index- P/E- EPS (ttm)-15.25 Insider Own1.80% Shs Outstand9.47M Perf Week-3.60%
Market Cap37.50M Forward P/E- EPS next Y-0.96 Insider Trans0.00% Shs Float9.31M Perf Month-18.30%
Income-126.60M PEG- EPS next Q-2.09 Inst Own40.10% Short Float6.39% Perf Quarter-23.78%
Sales153.70M P/S0.24 EPS this Y64.30% Inst Trans0.38% Short Ratio0.54 Perf Half Y-49.26%
Book/sh21.78 P/B0.17 EPS next Y87.40% ROA-19.10% Target Price- Perf Year-2.34%
Cash/sh- P/C- EPS next 5Y29.00% ROE-48.30% 52W Range2.53 - 9.84 Perf YTD-9.43%
Dividend- P/FCF- EPS past 5Y-58.80% ROI-14.80% 52W High-61.89% Beta0.65
Dividend %- Quick Ratio1.20 Sales past 5Y-20.90% Gross Margin72.90% 52W Low47.96% ATR0.38
Employees167 Current Ratio1.40 Sales Q/Q2.80% Oper. Margin-65.50% RSI (14)43.36 Volatility7.58% 8.88%
OptionableYes Debt/Eq1.15 EPS Q/Q-333.90% Profit Margin-82.30% Rel Volume0.17 Prev Close3.87
ShortableYes LT Debt/Eq0.82 EarningsAug 05 AMC Payout- Avg Volume1.11M Price3.75
Recom2.00 SMA20-6.24% SMA50-9.66% SMA200-24.65% Volume188,948 Change-3.10%
Jun-17-21Upgrade H.C. Wainwright Neutral → Buy $5 → $10
Aug-14-19Downgrade H.C. Wainwright Buy → Neutral $31 → $6
May-23-19Initiated Wedbush Neutral
Dec-11-18Downgrade Goldman Neutral → Sell
Aug-07-18Reiterated Stifel Hold $15 → $25
Feb-16-18Upgrade Piper Jaffray Neutral → Overweight
Jan-17-18Reiterated H.C. Wainwright Buy $34 → $31
Nov-28-17Resumed Piper Jaffray Neutral $22
Nov-16-17Downgrade Stifel Buy → Hold $26 → $15
Nov-16-17Downgrade Raymond James Mkt Perform → Underperform
Nov-09-17Initiated Oppenheimer Perform
Nov-08-17Initiated H.C. Wainwright Buy $35
Oct-06-17Resumed Goldman Sell $20
Jul-11-17Initiated Jefferies Hold
Apr-03-17Downgrade JP Morgan Overweight → Neutral
Feb-15-17Upgrade Goldman Sell → Neutral
Nov-30-16Upgrade JP Morgan Neutral → Overweight
Oct-04-16Resumed Leerink Partners Mkt Perform $25
Mar-30-16Initiated Goldman Sell
Sep-01-15Initiated Raymond James Mkt Perform
Jul-30-21 04:01PM  
Jul-27-21 03:02PM  
Jul-23-21 07:28AM  
Jul-22-21 04:01PM  
Jun-18-21 10:46PM  
Jun-16-21 07:00AM  
May-06-21 05:15PM  
Apr-29-21 04:30PM  
Apr-27-21 12:00PM  
Apr-20-21 09:46AM  
Apr-12-21 07:00AM  
Apr-01-21 07:51AM  
Mar-12-21 10:01AM  
Mar-11-21 08:52AM  
Mar-10-21 11:30AM  
Mar-08-21 11:12PM  
Mar-05-21 08:15AM  
Mar-04-21 05:45PM  
Mar-03-21 12:52PM  
Mar-02-21 08:43AM  
Feb-26-21 10:10AM  
Feb-25-21 07:00AM  
Feb-19-21 07:00AM  
Feb-11-21 11:12AM  
Feb-10-21 10:21AM  
Feb-08-21 12:40PM  
Feb-04-21 11:48AM  
Feb-02-21 03:23PM  
Feb-01-21 10:28AM  
Jan-28-21 10:12AM  
Jan-27-21 11:13AM  
Jan-25-21 09:28AM  
Jan-22-21 09:02AM  
Jan-21-21 12:16PM  
Jan-20-21 12:18PM  
Jan-15-21 08:19PM  
Jan-14-21 12:34PM  
Jan-13-21 07:25AM  
Jan-12-21 04:07PM  
Jan-11-21 04:20PM  
Dec-31-20 04:19PM  
Dec-21-20 12:00PM  
Dec-07-20 10:22PM  
Dec-03-20 08:53AM  
Nov-23-20 10:24AM  
Nov-16-20 09:48AM  
Nov-08-20 07:07AM  
Nov-03-20 05:15PM  
Nov-02-20 10:17AM  
Oct-27-20 07:00AM  
Oct-26-20 12:31PM  
Oct-20-20 11:17AM  
Sep-29-20 11:25AM  
Sep-17-20 07:00AM  
Aug-04-20 06:15PM  
Jul-31-20 12:45PM  
Jul-28-20 07:00AM  
Jul-08-20 06:40PM  
Jun-16-20 04:46PM  
Jun-12-20 09:36AM  
Jun-09-20 10:01AM  
Jun-04-20 11:31AM  
Jun-03-20 09:05AM  
May-06-20 07:23PM  
May-05-20 06:15PM  
Apr-28-20 07:00AM  
Apr-24-20 11:49AM  
Apr-16-20 05:45PM  
Apr-07-20 05:50PM  
Apr-03-20 08:31AM  
Apr-02-20 10:08AM  
Mar-30-20 08:06AM  
Mar-17-20 12:00PM  
Mar-14-20 11:30AM  
Feb-24-20 07:00AM  
Feb-18-20 01:44AM  
Feb-14-20 11:57AM  
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.